BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Seven analysts give BioAge Labs a consensus “Moderate Buy” rating, with six buys and one sell. The average 12-month price target is $36.57, though individual targets range from $21 to $35 in recent updates.
• Institutional interest has increased: BlackRock and Jupiter Topco initiated sizable positions during the second quarter, while Janus Henderson increased its stake by 411.8%.
• The stock remains under pressure and the company is unprofitable: BIOA opened at $7.09, well below its 52-week high of $25.95, and reported a quarterly loss of $0.58 per share. BioAge forecasts a full-year loss of $2.45 per share as it develops its lead aging-related therapy, azelaprag.

Shares of BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $36.57.

Several research firms recently commented on BIOA. Roth Capital reissued a "buy" rating and set a $25.00 price objective on shares of BioAge Labs in a research note on Wednesday, September 9th. Needham & Company LLC decreased their target price on shares of BioAge Labs from $50.00 to $35.00 and set a "buy" rating for the company in a research note on Friday, July 31st. Wall Street Zen upgraded shares of BioAge Labs from a "strong sell" rating to a "sell" rating in a report on Sunday, September 13th. Jefferies Financial Group set a $21.00 price target on BioAge Labs in a research note on Friday, July 31st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st.

Hedge Funds Weigh In On BioAge Labs

Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in BioAge Labs during the 2nd quarter valued at about $69,831,000. Jupiter Topco LLC purchased a new stake in BioAge Labs in the second quarter valued at approximately $52,597,000. Janus Henderson Group PLC boosted its position in BioAge Labs by 411.8% in the first quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock valued at $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Walleye Capital LLC acquired a new position in BioAge Labs in the 2nd quarter worth approximately $8,686,000. Finally, Stempoint Capital LP purchased a new position in BioAge Labs during the 1st quarter worth approximately $5,923,000.

BioAge Labs Stock Performance

BIOA opened at $7.09 on Thursday. BioAge Labs has a 52-week low of $5.04 and a 52-week high of $25.95. The stock has a market capitalization of $325.43 million, a PE ratio of -2.98 and a beta of 0.94. The stock's 50 day moving average price is $10.92 and its 200-day moving average price is $16.21.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%.The company had revenue of $2.45 million during the quarter. Research analysts forecast that BioAge Labs will post -2.45 EPS for the current fiscal year.

BioAge Labs Company Profile

BioAge Labs, Inc NASDAQ: BIOA is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company's lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.